

# Contents

|           |   |            |
|-----------|---|------------|
| <b>1</b>  | <b>von Recklinghausen Disease: 130 Years . . . . .</b>  | <b>1</b>   |
|           | Vincent M. Riccardi   |            |
| <b>2</b>  | <b>Clinical Diagnosis and Atypical Forms of NF1 . . . . .</b>   | <b>17</b>  |
|           | Sirkku Peltonen and Minna Pöyhönen  |            |
| <b>3</b>  | <b>Management and Treatment of “Complex Neurofibromatosis 1” . . .</b>  | <b>31</b>  |
|           | Rosalie E. Ferner and Susan M. Huson  |            |
| <b>4</b>  | <b>Mortality in Neurofibromatosis 1 . . . . .</b>   | <b>47</b>  |
|           | Gareth R. Evans   |            |
| <b>5</b>  | <b>The Cognitive Profile of NF1 Children: Therapeutic<br/>Implications . . . . .</b>                                  | <b>55</b>  |
|           | Natalie A. Pride and Kathryn N. North   |            |
| <b>6</b>  | <b>Clinical Expression of NF1 in Monozygotic Twins . . . . .</b>  | <b>71</b>  |
|           | Elizabeth K. Schorry and Emily Sites  |            |
| <b>7</b>  | <b>Value of Whole Body MRI in Patients with NF1 . . . . .</b>   | <b>83</b>  |
|           | Victor-Felix Mautner  |            |
| <b>8</b>  | <b>Quality of Life in NF1 . . . . .</b>   | <b>93</b>  |
|           | Patricia Birch and J.M. Friedman  |            |
| <b>9</b>  | <b><i>NF1</i> Gene: Promoter, 5' UTR, and 3' UTR . . . . .</b>  | <b>105</b> |
|           | Hua Li and Margaret R. Wallace  |            |
| <b>10</b> | <b>The Germline Mutational Spectrum in Neurofibromatosis Type 1<br/>and Genotype–Phenotype Correlations . . . . .</b> | <b>115</b> |
|           | David N. Cooper and Meena Upadhyaya   |            |
| <b>11</b> | <b>Splicing Mechanisms and Mutations in the <i>NF1</i> Gene . . . . .</b>   | <b>135</b> |
|           | Marco Baralle and Diana Baralle   |            |

|           |   |            |
|-----------|---|------------|
| <b>12</b> | <b><i>NF1</i> Germline and Somatic Mosaicism . . . . .</b>  | <b>151</b> |
|           | Ludwine Messiaen and Jing Xie   |            |
| <b>13</b> | <b>Deep Intronic <i>NF1</i> Mutations and Possible Therapeutic Interventions . . . . .</b>  | <b>173</b> |
|           | Conxi Lázaro, Juana Fernández-Rodríguez, and Eduard Serra   |            |
| <b>14</b> | <b><i>NF1</i> Microdeletions and Their Underlying Mutational Mechanisms . . . . .</b>   | <b>187</b> |
|           | Hildegard Kehrer-Sawatzki and David N. Cooper   |            |
| <b>15</b> | <b>The Somatic Mutational Spectrum of the <i>NF1</i> Gene . . . . .</b>   | <b>211</b> |
|           | Meena Upadhyaya, Nadia Chuzhanova, and David N. Cooper  |            |
| <b>16</b> | <b>Relationship Between <i>NF1</i> and Constitutive Mismatch Repair Deficiency . . . . .</b>  | <b>235</b> |
|           | Katharina Wimmer  |            |
| <b>17</b> | <b>Insights into <i>NF1</i> from Evolution . . . . .</b>  | <b>253</b> |
|           | Britta Bartelt-Kirbach and Dieter Kaufmann  |            |
| <b>18</b> | <b>Modifier Genes in <i>NF1</i> . . . . .</b>   | <b>269</b> |
|           | Eric Pasmant, Dominique Vidaud, and Pierre Wolkenstein  |            |
| <b>19</b> | <b>Dissection of Complex Genetic and Epigenetic Interactions Underlying <i>NF1</i> Cancer Susceptibility Using Mouse Models . . . . .</b> | <b>287</b> |
|           | Georgette N. Jones and Karlyne M. Reilly  |            |
| <b>20</b> | <b>Neurofibromin: Protein Domains and Functional Characteristics . . . . .</b>  | <b>305</b> |
|           | Klaus Scheffzek and Stefan Welti  |            |
| <b>21</b> | <b>Molecular Basis of Bone Abnormalities in <i>NF1</i> . . . . .</b>  | <b>327</b> |
|           | David A. Stevenson and Florent Elefteriou   |            |
| <b>22</b> | <b><i>NF1</i>-Associated Optic Glioma . . . . .</b>   | <b>341</b> |
|           | Anne C. Solga and David H. Gutmann  |            |
| <b>23</b> | <b>Molecular Basis of Cardiovascular Abnormalities in <i>NF1</i> . . . . .</b>  | <b>353</b> |
|           | Brian K. Stansfield, David A. Ingram, Simon J. Conway, and Jan M. Friedman  |            |
| <b>24</b> | <b>Molecular Basis of Glomus Tumours . . . . .</b>  | <b>367</b> |
|           | Hilde Brems, Eric Legius, and Douglas R. Stewart  |            |
| <b>25</b> | <b>Pheochromocytoma and <i>NF1</i> . . . . .</b>  | <b>381</b> |
|           | Birke Bausch and Hartmut P.H. Neumann   |            |
| <b>26</b> | <b>Molecular and Cellular Basis of Human Cutaneous Neurofibromas and Their Development . . . . .</b>                                      | <b>393</b> |
|           | Juha Peltonen, Eeva-Mari Jouhilahti, and Sirkku Peltonen  |            |

|  |            |
|--|------------|
| <b>27 Somatic Copy Number Alterations: Gene and Protein Expression Correlates in NF1-Associated Malignant Peripheral Nerve Sheath Tumors . . . . .</b> | <b>405</b> |
| Meena Upadhyaya and David N. Cooper  |            |
| <b>28 Pathologic and Molecular Diagnostic Features of Peripheral Nerve Sheath Tumors in NF1 . . . . .</b>  | <b>429</b> |
| Anat Stemmer-Rachamimov and G. Petur Nielsen   |            |
| <b>29 Malignant Peripheral Nerve Sheath Tumors: Prognostic and Diagnostic Markers and Therapeutic Targets . . . . .</b>                                | <b>445</b> |
| Holly Meany, Brigitte C. Widemann, and Nancy Ratner  |            |
| <b>30 NF1 Mutations in Hematologic Cancers . . . . .</b>   | <b>469</b> |
| Tiffany Chang and Kevin Shannon  |            |
| <b>31 Legius Syndrome: Diagnosis and Pathology . . . . .</b>   | <b>487</b> |
| Hilde Brems, Ludwine Messiaen, and Eric Legius   |            |
| <b>32 The RASopathies: Syndromes of Ras/MAPK Pathway Dysregulation . . . . .</b>   | <b>497</b> |
| William E. Tidyman and Katherine A. Rauen  |            |
| <b>33 Advances in NF1 Animal Models and Lessons Learned . . . . .</b>  | <b>513</b> |
| Ophélie Maertens and Karen Cichowski   |            |
| <b>34 <i>Drosophila</i>: An Invertebrate Model of NF1 . . . . .</b>  | <b>523</b> |
| James A. Walker, Jean Y. Gouzi, and André Bernardis  |            |
| <b>35 Zebrafish Model for NF1 . . . . .</b>  | <b>535</b> |
| Arun Padmanabhan and Jonathan A. Epstein   |            |
| <b>36 Cell of Origin and the Contribution of Microenvironment in NF1 Tumorigenesis and Therapeutic Implications . . . . .</b>                          | <b>549</b> |
| Johanna Buchstaller, D. Wade Clapp, Luis F. Parada, and Yuan Zhu   |            |
| <b>37 Molecular and Cellular Approaches to Cognitive Impairments Associated with NF1 and Other Rasopathies . . . . .</b>                               | <b>569</b> |
| Yong-Seok Lee and Alcino J. Silva  |            |
| <b>38 Ras Signaling Pathway in Biology and Therapy of Malignant Peripheral Nerve Sheath Tumors . . . . .</b>   | <b>589</b> |
| Faris Farassati  |            |
| <b>39 MicroRNA and NF1 Tumorigenesis . . . . .</b>   | <b>611</b> |
| Adrienne M. Flanagan and Nadège Presneau   |            |
| <b>40 Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1 . . . . .</b>  | <b>625</b> |
| Bruce Korf, Brigitte Widemann, Maria T. Acosta, and Roger J. Packer  |            |

|           |  |            |
|-----------|--|------------|
| <b>41</b> | <b>The Role of NF1 Lay Foundations: Future Vision . . . . .</b>                              | <b>659</b> |
|           | Kim Hunter-Schaedle  |            |
| <b>42</b> | <b>Social Stigma in Neurofibromatosis 1 . . . . .</b>  | <b>673</b> |
|           | Joan Ablon   |            |
| <b>43</b> | <b>Personalized Medicine in NF1 . . . . .</b>  | <b>683</b> |
|           | David Viskochil  |            |
| <b>44</b> | <b>Neurofibromatosis Type 1: Future Directions<br/>(Where Do We Go from Here?) . . . . .</b> | <b>691</b> |
|           | Luis F. Parada   |            |
|           | <b>Index . . . . .</b>   | <b>699</b> |

Neurofibromatosis Type 1

Molecular and Cellular Biology

Upadhyaya, M.; Cooper, D. (Eds.)

2012, XVI, 717 p. 75 illus., 60 illus. in color., Hardcover

ISBN: 978-3-642-32863-3